Joint Formulary & PAD

Tiotropium (Braltus Zonda) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Tiotropium (Braltus Zonda)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
LAMA
Keywords :
LAMAs, chronic obstructive pulmonary disease, respiratory, long-acting muscarinic antagonist
Brand Names Include :
Braltus Zonda
Important Information :

Safety concerns with device. Combination of LAMA and LABA recommended in COPD.

Not for initiation in new patients.

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
4

Other Indications

Below are listed other indications that Tiotropium (Braltus Zonda) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

The tiotropium Braltus device is NOT a locally preferred option. See below for preferred devices.

The locally preferred LAMA devices are as follows:

  • Spiriva Respimat (tiotropium soft mist inhaler). Re-usable device.
  • Incruse Ellipta (Umeclidinium DPI)
  • Seebri Breezhaler (Glycopyrronium DPI)
  • Eklira Genuair (Aclidinium DPI)

Devices should be prescribed by BRAND

See full COPD guidelines for more information